Hepatic microsomal UDP-glucuronosyltransferase (UGT) activities in the microminipig

Biopharmaceutics and Drug Disposition

Volumn 35, Issue 6, 2014, Pages 313-320

  Higashi, Eriko ^a   Ando, Akihiro ^a   Iwano, Shunsuke ^a   Murayama, Norie ^b   Yamazaki, Hiroshi ^b   Miyamoto, Yohei ^a  

^a TORAY INDUSTRIES INC   (Japan)

^b SHOWA PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Glucuronidation; Microminipig; Species differences; UGT

Indexed keywords

ESTRADIOL; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A4; GLUCURONOSYLTRANSFERASE 1A6; GLUCURONOSYLTRANSFERASE 1A9; GLUCURONOSYLTRANSFERASE 2B7; IMIPRAMINE; MORPHINE; PROPOFOL; SEROTONIN; URIDINE DIPHOSPHATE; ZIDOVUDINE; GLUCURONIDE;

ANIMAL EXPERIMENT; ARTICLE; CATALYSIS; COMPARATIVE STUDY; DOG; DRUG GLUCURONIDATION; ENZYME ACTIVITY; HAPLORHINI; HUMAN; IN VITRO STUDY; LIVER MICROSOME; MINIPIG; MOUSE; NONHUMAN; RAT; ADULT; AGED; ANIMAL; FEMALE; INSTITUTE FOR CANCER RESEARCH MOUSE; LIQUID CHROMATOGRAPHY; MACACA FASCICULARIS; MALE; METABOLISM; MIDDLE AGED; PIG; SPECIES DIFFERENCE; SPRAGUE DAWLEY RAT; TANDEM MASS SPECTROMETRY; YOUNG ADULT;

ADULT; AGED; ANIMALS; CHROMATOGRAPHY, LIQUID; DOGS; ESTRADIOL; FEMALE; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HUMANS; IMIPRAMINE; MACACA FASCICULARIS; MALE; MICE, INBRED ICR; MICROSOMES, LIVER; MIDDLE AGED; MORPHINE; PROPOFOL; RATS, SPRAGUE-DAWLEY; SEROTONIN; SPECIES SPECIFICITY; SWINE; SWINE, MINIATURE; TANDEM MASS SPECTROMETRY; YOUNG ADULT; ZIDOVUDINE;

EID: 84922260907     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.1898     Document Type: Article

References (27)

1. Forster R, Bode G, Ellegaard L, van der Laan JW. The RETHINK project on minipigs in the toxicity testing of new medicines and chemicals: conclusions and recommendations. J Pharmacol Toxicol Methods 2010; 62: 236-242. doi:10.1016/j.vascn.2010.05.008.
2. Miyoshi N, Horiuchi M, Inokuchi Y, et al. Novel microminipig model of atherosclerosis by high fat and high cholesterol diet, established in Japan. In Vivo 2010; 24: 671-680.
3. Kaneko N, Itoh K, Sugiyama A, Izumi Y. Microminipig, a non-rodent experimental animal optimized for life science research: preface. J Pharmacol Sci 2011; 115: 112-114.
4. Sugiyama A, Nakamura Y, Akie Y, et al. Microminipig, a non-rodent experimental animal optimized for life science research: in vivo proarrhythmia models of drug-induced long QT syndrome: development of chronic atrioventricular block model of microminipig. J Pharmacol Sci 2011; 115: 122-126.
5. Murayama N, Kaneko N, Horiuchi K, et al. Cytochrome P450-dependent drug oxidation activity of liver microsomes from microminipigs, a possible new animal model for humans in non-clinical studies. Drug Metab Pharmacokinet 2009; 24: 404-408.
6. Mackenzie PI, BockKW, Burchell B, et al. Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenet Genomics 2005; 15: 677-685.
7. Williams JA, Hyland R, Jones BC, et al. Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos 2004; 32: 1201-1208.
8. Shiratani H, Katoh M, Nakajima M, Yokoi T. Species differences in UDP-glucuronosyltransferase activities in mice and rats. Drug Metab Dispos 2008; 36: 1745-1752. doi:10.1124/dmd.108.021469.
9. Soars MG, Riley RJ, Burchell B. Evaluation of the marmoset as a model species for drug glucuronidation. Xenobiotica 2001; 31: 849-860.
10. Liang SC, Ge GB, Liu HX, et al. Determination of propofol UDP-glucuronosyltransferase (UGT) activities in hepatic microsomes from different species by UFLC-ESI-MS. J Pharm Biomed Anal 2011; 54: 236-241. doi:10.1016/j.jpba.2010.07.049.
11. Sisenwine SF, Tio CO, Hadley FV, Liu AL, Kimmel HB, Ruelius HW. Species-related differences in the stereoselective glucuronidation of oxazepam. Drug Metab Dispos 1982; 10: 605-608.
12. Ghosheh O, Hawes EM. Microsomal N-glucuronidation of nicotine and cotinine: human hepatic interindividual, human intertissue, and interspecies hepatic variation. Drug Metab Dispos 2002; 30: 1478-1483.
13. Yu J, Han JC, Hua LM, Gao YJ. In vitro characterization of glucuronidation of vanillin: identification of human UDP-glucuronosyltransferases and species differences. Phytother Res 2013; 27: 1392-1397. doi:10.1002/ptr.4885.
14. Miyake Y, Mayumi K, Jinno H, Tanaka-Kagawa T, Narimatsu S, Hanioka N. cDNA cloning and functional analysis of minipig uridine diphosphate-glucuronosyltransferase 1A1. Biol Pharm Bull 2013; 36: 452-461.
15. Lötsch J, Geisslinger G. Morphine-6-glucuronide: an analgesic of the future? Clin Pharmacokinet 2001; 40: 485-499.
16. Kosoglou T, Statkevich P, Johnson-Levonas AO, Paolini JF, Bergman AJ, Alton KB. Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet 2005; 44: 467-494.
17. Shitara Y, Hirano M, Sato H, Sugiyama Y. Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1: SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J Pharmacol Exp Ther 2004; 311: 228-236.
18. Ogilvie BW, Zhang D, Li W, et al. Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions. Drug Metab Dispos 2006; 34: 191-197.
19. Chiu SH, Huskey SW. Species differences in N-glucuronidation. Drug Metab Dispos 1998; 26: 838-847.
20. Nakajima M, Tanaka E, Kobayashi T, Ohashi N, Kume T, Yokoi T. Imipramine N-glucuronidation in human liver microsomes: biphasic kinetics and characterization of UDP-glucuronosyltransferase isoforms. Drug Metab Dispos 2002; 30: 636-642.
21. Zhou D, Guo J, Linnenbach AJ, Booth-Genthe CL, Grimm SW. Role of human UGT2B10 in N-glucuronidation of tricyclic antidepressants, amitriptyline, imipramine, clomipramine, and trimipramine. Drug Metab Dispos 2010; 38: 863-870.
22. Kato Y, Izukawa T, Oda S, et al. Human UDP-glucuronosyltransferase (UGT) 2B10 in drug N-glucuronidation: substrate screening and comparison with UGT1A3 and UGT1A4. Drug Metab Dispos 2013; 41: 1389-1397.
23. Krishnaswamy S, Duan SX, Von Moltke LL, et al. Serotonin (5-hydroxytryptamine) glucuronidation in vitro: assay development, human liver microsome activities and species differences. Xenobiotica 2003; 33: 169-180.
24. Lépine J, Bernard O, Plante M, et al. Specificity and regioselectivity of the conjugation of estradiol, estrone, and their catecholestrogen and methoxyestrogen metabolites by human uridine diphospho-glucuronosyltransferases expressed in endometrium. J Clin Endocrinol Metab 2004; 89: 5222-5232.
25. Soars MG, Petullo DM, Eckstein JA, Kasper SC, Wrighton SA. An assessment of UDP-glucuronosyltransferase induction using primary human hepatocytes. Drug Metab Dispos 2004; 32: 140-148.
26. Nagar S, Remmel RP, Hebbel RP, Zimmerman CL. Metabolism of opioids is altered in liver microsomes of sickle cell transgenic mice. Drug Metab Dispos 2004; 32: 98-104.
27. Coughtrie MW, Burchell B, Leakey JE, Hume R. The inadequacy of perinatal glucuronidation: immunoblot analysis of the developmental expression of individual UDP-glucuronosyltransferase isoenzymes in rat and human liver microsomes. Mol Pharmacol 1988; 34: 729-735.